^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSLN expression

    i
    Entrez ID:
    10232
    Related biomarkers:
    Expression
    Others
    Apply
    A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) (NCT06051695)
    Phase 1/2
    A2 Biotherapeutics Inc.
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/03/2024
    Primary completion :
    06/01/2028
    Completion :
    06/01/2029
    HLA-A • MSLN
    |
    MSLN expression • HLA-A*02
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (NCT02414269)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/01/2015
    Primary completion :
    04/30/2025
    Completion :
    04/30/2025
    PD-L1 • MSLN
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide • cyclophosphamide intravenous • iCasp9M28z T cell infusion
    SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (NCT05568680)
    Phase 1
    Verismo Therapeutics
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    03/30/2023
    Primary completion :
    03/15/2026
    Completion :
    03/30/2026
    MSLN
    |
    MSLN expression
    |
    SynKIR-110
    Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (NCI10208) (NCT03816358)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    12/09/2019
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)
    Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors (NCT05693844)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    01/20/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    MSLN
    |
    MSLN expression
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • CD40 ligand expressing MSLN-CAR T
    Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (NCT04577326)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/01/2024
    Initiation :
    09/30/2020
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    MSLN
    |
    MSLN expression
    |
    cyclophosphamide • ATA2271 • cyclophosphamide intravenous • engineered autologous T cells
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849)
    Phase 1/2
    TCR2 Therapeutics
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    06/21/2022
    Primary completion :
    10/30/2028
    Completion :
    10/30/2028
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510
    Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852)
    Phase 1/2
    TCR2 Therapeutics
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    04/15/2019
    Primary completion :
    11/02/2028
    Completion :
    11/02/2028
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
    Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin (NCT05375825)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/01/2024
    Initiation :
    02/06/2024
    Primary completion :
    12/18/2024
    Completion :
    12/18/2024
    MSLN
    |
    MSLN expression • MSLN positive
    |
    LMB-100
    CAR T Cells in Mesothelin Expressing Cancers (NCT03054298)
    Phase 1
    University of Pennsylvania
    Active, not recruiting
    Last update posted :
    01/24/2024
    Initiation :
    04/06/2017
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    PD-L1
    |
    MSLN expression
    |
    cyclophosphamide • fludarabine IV • TmMSTN-01
    CAR T Cells in Mesothelin-Expressing Breast Cancer (NCT05623488)
    Phase 1
    University of Pennsylvania
    Recruiting
    Last update posted :
    01/24/2024
    Initiation :
    02/06/2023
    Primary completion :
    02/01/2025
    Completion :
    02/01/2038
    HER-2 • ER • PGR • MSLN
    |
    ER positive • HER-2 negative • ER negative • MSLN expression • PGR positive • PGR negative
    Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (NCT03126630)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    10/04/2018
    Primary completion :
    07/08/2023
    Completion :
    09/21/2024
    PD-L1 • MSLN
    |
    PD-L1 expression • MSLN expression
    |
    Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)
    A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (NCT05508334)
    Phase 1
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    01/10/2024
    Initiation :
    01/30/2023
    Primary completion :
    06/30/2024
    Completion :
    12/30/2024
    MSLN
    |
    MSLN expression
    |
    misitatug blivedotin (RC88)
    Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (NCT04809766)
    Phase 1
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    01/09/2024
    Initiation :
    12/14/2021
    Primary completion :
    06/30/2024
    Completion :
    06/30/2025
    HLA-A • MSLN
    |
    MSLN expression • HLA-A*02
    |
    cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ • cyclophosphamide intravenous
    A Study of TAK-103 in Adult With Solid Tumors (NCT05164666)
    Phase 1
    Takeda
    Active, not recruiting
    Last update posted :
    12/27/2023
    Initiation :
    01/05/2022
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    MSLN
    |
    MSLN expression
    |
    NIB103
    Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers (NCT05779917)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    11/15/2023
    Initiation :
    03/10/2023
    Primary completion :
    03/10/2026
    Completion :
    03/10/2033
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Mesothelin/GPC3/GUCY2C-CAR-T
    Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC) (NCT01393483)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    10/03/2023
    Initiation :
    03/01/2011
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    MSLN
    |
    MSLN expression • MSLN positive
    Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (NCT04727554)
    Phase 1
    Amgen
    Completed
    Last update posted :
    09/22/2023
    Initiation :
    04/29/2021
    Primary completion :
    06/05/2023
    Completion :
    06/05/2023
    MSLN
    |
    MSLN expression • MSLN positive
    |
    inezetamab (AMG994) • zeluvalimab (AMG 404)
    Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors (NCT04034238)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/01/2023
    Initiation :
    08/29/2019
    Primary completion :
    12/01/2020
    Completion :
    11/19/2021
    MSLN
    |
    MSLN expression
    |
    tofacitinib • LMB-100
    T-Cell Therapy for Advanced Breast Cancer (NCT02792114)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    06/30/2023
    Initiation :
    06/01/2016
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    HER-2 • PD-L1 • MSLN
    |
    HER-2 negative • MSLN expression
    |
    cyclophosphamide • cyclophosphamide intravenous • rimiducid (AP1903)
    A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers (NCT05403554)
    Phase 1
    Light Chain Bioscience - Novimmune SA
    Recruiting
    Last update posted :
    05/29/2023
    Initiation :
    04/29/2022
    Primary completion :
    06/30/2025
    Completion :
    09/30/2025
    MSLN
    |
    MSLN expression
    |
    NI-1801
    Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma (NCT05856643)
    Phase 1
    Shantou University Medical College
    Not yet recruiting
    Last update posted :
    05/12/2023
    Initiation :
    06/01/2023
    Primary completion :
    06/01/2025
    Completion :
    12/30/2025
    MSLN
    |
    MSLN expression
    |
    SZ011
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (NCT03198052)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2024
    Completion :
    08/01/2026
    EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA
    |
    MSLN expression • EGFR positive • GPC3 expression
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) (NCT03102320)
    Phase 1b
    Bayer
    Completed
    Last update posted :
    06/30/2022
    Initiation :
    05/26/2017
    Primary completion :
    09/16/2020
    Completion :
    07/26/2021
    MSLN
    |
    MSLN expression
    |
    cisplatin • gemcitabine • anetumab ravtansine (BAY 94-9343)
    Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer (NCT03023722)
    Phase 2
    Yale University
    Completed
    Last update posted :
    10/28/2021
    Initiation :
    05/11/2017
    Primary completion :
    08/06/2019
    Completion :
    12/11/2019
    MSLN
    |
    MSLN expression
    |
    anetumab ravtansine (BAY 94-9343)
    The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer (NCT03814447)
    Phase 1
    Shanghai 6th People's Hospital
    Recruiting
    Last update posted :
    08/10/2021
    Initiation :
    08/16/2019
    Primary completion :
    01/01/2023
    Completion :
    01/01/2023
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells • cyclophosphamide intravenous
    Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. (NCT01439152)
    Phase 1
    Bayer
    Completed
    Last update posted :
    07/09/2021
    Initiation :
    09/07/2011
    Primary completion :
    12/31/2016
    Completion :
    07/30/2019
    MSLN
    |
    MSLN expression
    |
    anetumab ravtansine (BAY 94-9343)
    Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment (NCT02696642)
    Phase 1
    Bayer
    Completed
    Last update posted :
    07/09/2021
    Initiation :
    04/14/2016
    Primary completion :
    07/31/2018
    Completion :
    08/19/2019
    MSLN
    |
    MSLN expression
    |
    anetumab ravtansine (BAY 94-9343)
    Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) (NCT02610140)
    Phase 2
    Bayer
    Completed
    Last update posted :
    11/04/2020
    Initiation :
    12/03/2015
    Primary completion :
    05/31/2017
    Completion :
    09/06/2019
    MSLN
    |
    MSLN expression
    |
    pemetrexed • vinorelbine tartrate • anetumab ravtansine (BAY 94-9343)
    Phase 1 Study of Mesothelin-ADC (NCT02884726)
    Phase 1
    Bristol-Myers Squibb
    Completed
    Last update posted :
    03/19/2020
    Initiation :
    10/14/2016
    Primary completion :
    09/06/2017
    Completion :
    09/06/2017
    MSLN
    |
    MSLN expression
    |
    BMS-986148
    SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma (NCT01362790)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    06/06/2019
    Initiation :
    05/11/2011
    Primary completion :
    08/03/2016
    Completion :
    08/07/2017
    ALK • MSLN
    |
    EGFR mutation • MSLN expression • ALK translocation
    |
    cyclophosphamide • pentostatin • SS1(dsFv)-PE38 • cyclophosphamide intravenous
    MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer (NCT03916679)
    Phase 1/2
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    04/16/2019
    Initiation :
    04/20/2019
    Primary completion :
    04/20/2022
    Completion :
    04/20/2023
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV
    MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer (NCT03799913)
    Phase 1
    Zhejiang University
    Unknown status
    Last update posted :
    04/10/2019
    Initiation :
    04/10/2019
    Primary completion :
    10/01/2021
    Completion :
    04/01/2022
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells
    Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer (NCT03692637)
    Phase 1
    Allife Medical Science and Technology Co., Ltd.
    Unknown status
    Last update posted :
    01/31/2019
    Initiation :
    03/01/2019
    Primary completion :
    11/01/2020
    Completion :
    11/01/2021
    PD-L1 • PD-1 • MSLN
    |
    MSLN expression • MSLN positive
    |
    MSLN CAR-T • anti-Mesothelin CAR NK Cells
    PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor (PAEMCMPAST) (NCT03615313)
    Phase 1/2
    Shanghai Cell Therapy Research Institute
    Unknown status
    Last update posted :
    08/03/2018
    Initiation :
    08/06/2018
    Primary completion :
    08/03/2020
    Completion :
    12/03/2020
    MSLN
    |
    MSLN expression
    |
    cyclophosphamide • fludarabine IV • BZD1901
    Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies (NCT02485119)
    Phase 1
    Bayer
    Completed
    Last update posted :
    06/04/2018
    Initiation :
    08/14/2015
    Primary completion :
    04/28/2017
    Completion :
    07/04/2017
    MSLN
    |
    MSLN expression
    |
    anetumab ravtansine (BAY 94-9343)
    A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma (NCT01051934)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/02/2017
    Initiation :
    12/29/2009
    Primary completion :
    09/28/2011
    Completion :
    09/28/2011
    MSLN
    |
    MSLN expression
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • SS1(dsFv)-PE38